摘要
目的探讨第二代酪氨酸激酶抑制剂(TK-Ⅱ)甲磺酸伊马替尼联合亲缘异基因造血干细胞移植(allo-HSCT)治疗高危Ph染色体阳性白血病的疗效。方法将符合标准的48例高危Ph染色体阳性白血病患者随机分成两组各24例。观察组给予TK-Ⅱ联合allo-HSCT治疗;对照组给予单纯allo-HSCT治疗。比较两组患者造血重建、移植物抗宿主病(GVHD)、长期存活情况。结果观察组患者急性GVHD总发生率为70.8%,显著高于对照组的41.7%(P<0.05)。观察组患者慢性GVHD中局限性发生率为16.7%,显著低于对照组的41.7%(P<0.05)。观察组患者慢性GVHD的总发生率为29.2%,显著低于对照组的58.2%(P<0.05)。观察组患者2年存活率为62.5%,显著性高于对照组的33.3%(P<0.05)。结论 TK-Ⅱ联合allo-HSCT治疗高危Ph染色体阳性白血病能够有效促进手术的成功,提高患者的存活率与生活质量,降低疾病的复发率,值得在临床上推广使用。
Objective To integrative clinical efficacy and safety of TK- Ⅱ combined with allo-HSCT in treatment of high risk Ph chromosome positive leukemia. Methods 48 patients with this disease were randomly divided into two groups.Patients in observed group（24cases） received the treatment of TK- Ⅱ combined with allo-HSCT,while others（24cases） received the treatment of allo-HSCT only. Results The total incidence of acute GVHD in observed group was 70.8% which was significantly higher than that of 41.7% in control group（P〈 0.05）.The incidence of chronic limited GVHD in observed group was 16.7%,which was significantly lower than that of 41.7% in control group（P〈 0.05）.The total incidence of chronic GVHD in observed group was 29.2%,which was significantly lower than that of 58.2% in control group（P〈 0.05）.The 2-year survival rate of the observed group was 62.5%,which was significantly higher than that of 33.3% in control group（P〈 0.05）. Conclusion TK- Ⅱ can effectively promote the success of the operation,improve the patients survival rate and life quality,reduce the recurrence of the disease.
出处
《中国医药科学》
2015年第24期39-41,56,共4页
China Medicine And Pharmacy
